Your search history is turned on.
Date: May 8, 2024 19:07:20 EST Jurisdictions: Alberta, British Columbia, Quebec
LSL DCI EN LSL Pharma Group Acquisition of a Quebec Competitor REVISED MATERIAL CHANGE REPORT PURSUANT TO SECTION 7.1 OF NATIONAL INSTRUMENT 51-102 RESPECTING CONTINUOUS DISCLOSURE OBLIGATIONS ITEM 1 Name and Address of Company LSL Pharma Group Inc. (the Company or LSL Pharma Group) 540, dAvaugour Street, Suite 1800 Boucherville (Qub...
Date: May 6, 2024 Jurisdictions: Alberta, British Columbia, Quebec
LSL Pharma Group Enters Into Binding Agreement to Acquire Quebec Competitor Transaction expected to increase annual revenues by 15-20% Acquisition to boost overall profitability Transaction expected to close by end of Q2-24 BOUCHERVILLE, Qubec, May 06, 2024 -- LSL PHARMA GROUP INC. (TSXV: LSL) ("the Company" or "LSL Pharma"), a Canadian integrated pharmaceutical company, is pleased to announce...
Date: May 1, 2024 Jurisdictions: Ontario, Quebec
Crer la dclaration de placement avec dispense (Annexe 45-106A1) Annexe 45- 106A1 Dclaration de placement avec dispense RUBRIQUE 1 - TYPE DE DCLARATION Nouvelle dclaration Dclaration modifie Le cas chant, indiquer la date de dpt de la dclaration modifie. (AAAA-MM-JJ) RUBRIQUE 2 - PARTIE ATTESTANT LA DCLARATION Indiquer la partie qui ...
Date: May 1, 2024 Jurisdictions: Alberta, British Columbia, Quebec
LSL - DCI EN - Appointment_Closing 2nd Tranche MATERIAL CHANGE REPORT PURSUANT TO SECTION 7.1 OF NATIONAL INSTRUMENT 51-102 RESPECTING CONTINUOUS DISCLOSURE OBLIGATIONS ITEM 1 Name and Address of Company LSL Pharma Group Inc. (the Company or LSL Pharma Group) 540, dAvaugour Street, Suite 1800 Boucherville (Qubec) J4B 0G6 ITEM 2 Date of ...
Date: April 30, 2024 Jurisdictions: Alberta, British Columbia, Quebec
LSL Pharma Group Reports Its Fourth Quarter and Year-End 2023 Results and Highlights FY-2023 Revenues increased by 22% at $10.0 million compared to $8.2 million for FY-2022, a $1.8 million increase. Gross margins for FY-2023 up $3.8 million compared to FY-2022 Net loss for FY-2023 of $8.5 million compared to $8.1 million for FY-2022 Q4-2023 Revenues of $3.5 million, up 51% over Q4-2022 revenues o...
Date: April 29, 2024 Jurisdictions: Alberta, British Columbia, Quebec
Consolidated Financial Statements of LSL PHARMA GROUP INC. (formerly Corporation Exploration ledor) Years ended December 31, 2023 and 2022 LSL PHARMA GROUP INC. Table of Contents Page Independent Auditors Report Consolidated financial statements of LSL Pharma Group Inc. Conso...
Date: April 29, 2024 Jurisdictions: Alberta
Crer un document intitul Participation fee form Note: [01 Mar 2017] - The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative. FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ...
FORM 52-109FV2 CERTIFICATION OF ANNUAL FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Luc Mainville, Chief Financial Officer of LSL Pharma Group Inc., certify the following: 1. Review: I have reviewed the annual financial report and annual MD&A (together the annual filings) of LSL Pharma Group Inc. (the issuer) for the fiscal year ended December 31, 2023....
FORM 52-109FV2 CERTIFICATION OF ANNUAL FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Franois Roberge, Chief Executive Officer of LSL Pharma Group Inc., certify the following: 1. Review: I have reviewed the annual financial report and annual MD&A (together the annual filings) of LSL Pharma Group Inc. (the issuer) for the fiscal year ended December 31, 2...
MANITEX CAPITAL INC LSL PHARMA GROUP INC. Managements Discussion and Analysis for the three and twelve-month periods ended December 31, 2023 and 2022 1 MANAGEMENTS RESPONSIBILITY FOR FINANCIAL REPORTING The following is Managements Discussion and Analysis (MD&A) of the financial condition and operating results of LSL Pharma Group Inc. (LSL Pharma o...